<DOC>
	<DOCNO>NCT00647166</DOCNO>
	<brief_summary>To determine whether combination corticosteroid azathioprine achieve high remission rate lower subsequent relapse rate patient newly-diagnosed microscopic polyangiitis , polyarteritis nodosa eosinophilic granulomatosis polyangiitis ( Churg Strauss syndrome ) poor prognosis factor ( FFS=0 ) , without significantly increase rate adverse event , compare corticosteroid alone . The study hypothesis reduction absolute risk treatment failure relapse within first 24 month follow initiation therapy least 25 % .</brief_summary>
	<brief_title>Association Corticosteroid/Azathioprine Microscopic Polyangiitis/ Polyarteritis Nodosa Eosinophilic Granulomatosis With Polyangiitis ( Churg Strauss Syndrome )</brief_title>
	<detailed_description>Patients new diagnosis 1 ) microscopic polyangiitis , polyarteritis nodosa eosinophilic granulomatosis polyangiitis ( Churg Strauss syndrome ) 2 ) without factor poor prognosis accord French five factor score ( FFS - include creatininemia &gt; 140µmol/l , proteinuria &gt; 1 g/24 h , specific gastro-intestinal involvement , specific cardiomyopathy , CNS involvement ) include diagnosis within first 15 day follow initiation corticosteroid . Treatment randomly assign , centrally , receive double-blinded fashion . It consist combination azathioprine ( 2 mg/kg/day ) corticosteroid ( start 1 mg/kg/day 3 week progressively taper mean 50 week , vary accord patient 's weight ) , control group , corticosteroid therapy plus placebo . Duration azathioprine placebo 12 month , patient follow 12 additional month , yield total duration protocol 24 month entry patient . End point number patient achieve sustain remission suffer relapse 24 month study protocol . Based result early CHUSPAN trial similar patient treated corticosteroid alone , cumulative rate failure relapse estimate 40 % 24 month . The primary hypothesis CHUSPAN 2 reduction least 25 % rate combine parameter remission-treatment failure relapse 24 month . Based hypothesis , use bilateral test , significance level 5 % , beta level 80 % estimate 5 % lost-of-follow-up , 104 patient must include . Secondary end point include initial remission rate ( independently subsequent relapse ) , rate adverse event severity accord WHO toxicity grade system , number death , number patient could wean corticosteroid , area curve corticosteroid , different scale , BVAS ( activity disease ) , VDI ( damage ) , HAQ , SF36 , ADL evaluation need health care facility .</detailed_description>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Polyarteritis Nodosa</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>male female patient age 18 year new diagnosis microscopic polyangiitis , polyarteritis nodosa eosinophilic granulomatosis polyangiitis ( Churg Strauss syndrome ) , satisfy ACR 1990 and/or Chapel Hill Nomenclature criterion ( positive biopsy mandatory provide criterion fulfil ) factor poor prognosis accord French five factor score ( FFS=0 ) diagnosis within first 21 day follow initiation corticosteroid sign information consent form patient cover Health Insurance baseline physical examination patient microscopic polyangiitis , polyarteritis nodosa eosinophilic granulomatosis polyangiitis ( Churg Strauss syndrome ) one factor ( ) poor prognosis accord French five factor score ( FFS ≥ 1 ) patient polyarteritis nodosa ANCA , satisfy criterion microscopic polyangiitis patient clinically overt alveolar hemorrhage respiratory distress syndrome patient treat corticosteroid 15 day already receive another immunosuppressant relapse vasculitis vasculitis , especially secondary vasculitides vasculitis secondary associate viral infection , hepatitis B C virus , HIV malignancy pregnancy breast feeding , woman childbearing age willing contraindication receive contraception contraindication study agent need continue allopurinol patient take allopurinol consent deny inability receive information give consent participation another concomitant therapeutic trial affiliation general French health care system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Vasculitis</keyword>
	<keyword>Polyarteritis nodosa ( PAN )</keyword>
	<keyword>Microscopic polyangiitis ( MPA )</keyword>
	<keyword>Eosinophilic granulomatosis polyangiitis ( EGPA )</keyword>
	<keyword>Churg Strauss syndrome ( CSS )</keyword>
	<keyword>Azathioprine</keyword>
</DOC>